AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and (A3 Trial)

The goal of the AHEAD 3-45 Study is to determine whether treatment with BAN2401 is superior to placebo on change from baseline of the Preclinical Alzheimer’s disease (AD) Cognitive Composite 5 (PACC5) at 216 weeks of treatment, and determine whether treatment with BAN2401 is superior to placebo in reducing brain amyloid accumulation as measured by amyloid PET at 216 weeks of treatment.